Guidelines & Advice

What's New in Guidelines & Advice

All documents recently added to the Guidelines & Advice area within the last 6 months are available here, as well as any updated documents.

Postmastectomy Breast Reconstruction in Patients with Non-Metastatic Breast Cancer

Document Status: Current

ID: GL 17-10 v2

Version: 2

New

Mar 2025

Ontario Cervical Screening Program recommendations for cervical screening and colposcopy with human papillomavirus testing in Ontario

New

Mar 2025

Ontario Cervical Screening Program: Guidance for Vaginal Vault Testing

Document Status: Current

New

Mar 2025

T-Cell Engaging Antibodies: Management of Cytokine Release Syndrome (CRS) and Immune Effector-Associated Neurotoxicity Syndrome (ICANS)

Document Status: Current

New

Mar 2025

Ontario Cervical Screening Program: Interim guidance to support the transition years following the launch of human papillomavirus testing in Ontario: Cervical screening and colposcopy recommendations for people ages 21 to 24

Document Status: Current

New

Mar 2025

The Use of Molecular Tools for Identifying and Guiding Treatment of Cancers of Unknown Primary

Document Status: Current

ID: MOTAC-7

Jan 2025

Organizational Requirements for Acute Leukemia Service Providers in Ontario: Recommendations Report 2024

Document Status: Current

Version: 2

Dec 2024

An Endorsement of the ASTRO/ESTRO 2023 Guideline for the Treatment of Patients with Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer

Document Status: Current

ID: GL END 7-24

Nov 2024

An Endorsement of the 2023 European Association of Urology (EAU) -American Society of Clinical Oncology (ASCO) Guidelines on Penile Cancer

Document Status: Current

ID: Guideline Endorsement C50-CIDAP-2

Nov 2024

Endometrial Cancer Molecular Testing Recommendations Report

Document Status: Current

Version: 1

Nov 2024

Organizational Guidance for the Care of Patients with Central Nervous System Tumours in Ontario: Consensus Recommendations

Document Status: Current

ID: GL 9-11

Oct 2024

First-line treatment of advanced-stage Hodgkin lymphoma

Document Status: Current

ID: ES 6-25

Oct 2024